Podcast Episodes
Back to Search
Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC
2 years, 1 month ago
Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
2 years, 1 month ago
Episode 343: ESMO 2024 - TiNivo-2 Trial
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
2 years, 1 month ago
Episode 342: ESMO 2024 Preview with Silke Gillessen
Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024
2 years, 1 month ago
Episode 341: Hormone Resistance in Prostate Cancer
Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer
2 years, 2 months ago
Episode 341: Resistance to Hormone Therapy in Prostate Cancer
Nima Sharifi discusses data and hypotheses around mechanisms of resistance to ADT in prostate cancer
2 years, 2 months ago
Episode 340: Cancer Immunity Cycle Update
Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.
2 years, 2 months ago
Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU
María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.
2 years, 2 months ago
Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics
2 years, 2 months ago
Episode 337: Updated NCCN Guidelines in RCC
Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-…
2 years, 3 months ago